The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer

Gynecologic Oncology

Volumn 97, Issue 2, 2005, Pages 710-712

  Martino, Martin A ^a   Miller, Evan ^a   Grendys Jr , Edward C ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Florida Society of Gynecologic Oncologists   (United States)

Author keywords

Charcot Marie Tooth; Chemotherapy; Docetaxel; Ovarian cancer; Paclitaxel; Taxol; Taxotere

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CYSTADENOCARCINOMA; DISEASE EXACERBATION; DRIVING ABILITY; DRUG TOLERABILITY; FEMALE; GAIT DISORDER; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; NEUROTOXICITY; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; TREATMENT OUTCOME; WALKING; WRITING;

EID: 18144400374     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.01.017     Document Type: Article

References (15)

1. M.A. Bookman, B.E. Greer, and R.F. Ozols Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG 182-ICON 5 Int. J. Gynecol. Cancer 13 6 2003 (Nov-Dec) 735 740
2. A.M. Orejana-Garcia Charcot-Marie-Tooth disease and vincristine J. Am. Podiatr. Med. Assoc. 93 2003 229 233
3. Y. Hsu, A. Sood, and J.I. Sorosky Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: a case control analysis of toxicity Am. J. Clin. Oncol. 27 1 2004 (Feb) 14 18
4. National Cancer Institute: Common Terminology Criteria for Adverse Events Version 3.0 March 28, 2003. URL: http://www.fda.gov/cder/cancer/toxicityframe. htm.
5. Charcot-Marie-Tooth Disease Fact Sheet (online). 3/6/2004. URL: http://www.ninds.nih.gov/health_and_medical/disorders/charcot_doc.htm.
6. M. Abbruzzese, and G. Levi Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease Neurobiol. Dis. 16 1 2004 (Jun) 263 273
7. Canale Campbell's operative orthopaedics: Charcot-Marie-Tooth disease (peroneal muscular atrophy) Tenth ed. 2003 Mosby, Inc.
8. M.J. Piccart, K. Bertelsen, and G. Stuart Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int. J. Gynecol. Cancer 13 Suppl 2 2003 (Nov-Dec) 144 148
9. P.A. Vasey Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer J. Clin. Oncol. 21 10 Suppl 2003 (May 15) 136 144
10. P.G. Rose, J.A. Blessing, and H.G. Ball A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 88 2 2003 (Feb) 130 135
11. P.A. Vasey, G.C. Jayson, and A. Gordon Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma (SCOTROC) J. Natl. Cancer Inst. 96 22 2004 (Nov 17) 1682 1691
12. P. Ravdin, J. Erban, and J. Overmoyer Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer Annual Meeting ECCO/Abstract 670 2003
13. Ibid. 9
14. C. Williams, M. Collingwood, and I. Simera Short versus long duration infusions of paclitaxel for any adenocarcinoma Cochrane Database Syst. Rev. 1 2003 CD003911
15. V. Chaudhry Toxic neuropathy in patients with pre-existing neuropathy Neurology 60 2 2003 337 340